Portola Pharma (PTLA) Gets a Buy Rating from Citigroup

By Ryan Adsit

Citigroup analyst Yigal Nochomovitz maintained a Buy rating on Portola Pharma (PTLAResearch Report) today and set a price target of $44.00. The company’s shares closed last Monday at $27.03.

According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of 4.4% and a 43.7% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Atara Biotherapeutics, and Reata Pharmaceuticals.

Portola Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $40.25.

See today’s analyst top recommended stocks >>

Based on Portola Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $66.2 million. In comparison, last year the company had a GAAP net loss of $71.3 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.